TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen

TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

A number of other research firms have also weighed in on TLSI. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Canaccord Genuity Group increased their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, TriSalus Life Sciences presently has an average rating of “Hold” and an average target price of $11.00.

TriSalus Life Sciences Trading Down 4.8%

TriSalus Life Sciences stock opened at $4.52 on Friday. The firm has a market capitalization of $225.82 million, a P/E ratio of -2.24 and a beta of 0.42. TriSalus Life Sciences has a twelve month low of $3.42 and a twelve month high of $7.95. The stock’s fifty day simple moving average is $6.18 and its 200-day simple moving average is $5.27.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The company had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $11.76 million. Sell-side analysts predict that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TLSI. Police & Firemen s Retirement System of New Jersey purchased a new stake in TriSalus Life Sciences in the second quarter valued at $29,000. JPMorgan Chase & Co. increased its position in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at about $47,000. HighMark Wealth Management LLC purchased a new stake in shares of TriSalus Life Sciences in the 4th quarter valued at about $75,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at about $90,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.